Axsome Therapeutics Income from Continuous Operations 2014-2025 | AXSM

Axsome Therapeutics income from continuous operations from 2014 to 2025. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change

Axsome Therapeutics Income from Continuous Operations 2014-2025 | AXSM

Axsome Therapeutics income from continuous operations from 2014 to 2025. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$226.7B
Amgen (AMGN)$158.7B
Gilead Sciences (GILD)$139.7B
Vertex Pharmaceuticals (VRTX)$117.3B
Bristol Myers Squibb (BMY)$88.1B
CSL (CSLLY)$84.3B
GSK (GSK)$75.8B
Regeneron Pharmaceuticals (REGN)$58.9B
Alnylam Pharmaceuticals (ALNY)$51.1B
Argenex SE (ARGX)$41B
BioNTech SE (BNTX)$25.8B
Royalty Pharma (RPRX)$20.7B
Insmed (INSM)$20.4B
Biogen (BIIB)$18.8B
Illumina (ILMN)$16.3B
Genmab (GNMSF)$14.7B
Incyte (INCY)$14.6B
Genmab (GMAB)$13.9B
Moderna (MRNA)$11.4B
BioMarin Pharmaceutical (BMRN)$11.1B
QIAGEN (QGEN)$11B
Ascendis Pharma (ASND)$10.6B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Exelixis (EXEL)$9.8B
Verona Pharma American Depositary Share (VRNA)$8.9B
Exact Sciences (EXAS)$8.9B
Bio-Techne Corp (TECH)$8.6B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$7.7B
Halozyme Therapeutics (HALO)$7.4B